• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

    6/25/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email

    ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification. The regulatory approval for the blended polymer joins the earlier approval announced on March 13, 2025 for the delivery system component of FemBloc. The FemBloc System can now be marketed in the European Economic Area, which includes the 27 member states of the European Union and the 3 European Free Trade Association countries.

    "European approval of the entire FemBloc System represents a major milestone for Femasys and the field of women's health. It marks the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution, following a rigorous scientific evaluation of the technology. This achievement reflects years of dedication and underscores our commitment to bringing safe, accessible alternatives to traditional surgical options," stated Kathy Lee-Sepsick, Femasys' CEO and Founder. "Femasys is preparing to make FemBloc commercially available through strategic distribution partnerships in select countries in Europe beginning in Spain through our existing partners and will seek additional country approvals while continuing to enroll participants in our FDA IDE-approved late-stage pivotal trial for U.S. approval."

    About FemBloc

    FemBloc® is a revolutionary, first-of-its-kind non-surgical solution for permanent birth control, addressing a large unmet need in women's reproductive health. Delivered in-office through a patented delivery system, FemBloc places a proprietary blended polymer into both fallopian tubes, which safely degrades and forms natural scar tissue to permanently block them. In contrast to surgical sterilization, FemBloc eliminates the risks of anesthesia, infection, and recovery downtime, making it safer, more accessible, and significantly more cost-effective. With no comparable alternatives on the market, FemBloc represents a disruptive advancement with broad global potential. Learn more at www.FemBloc.com.

    About Femasys

    Femasys is a leading biomedical innovator focused on addressing critical unmet needs in women's health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data show FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1

    FemBloc® permanent birth control, the first and only non-surgical, in-office alternative to centuries-old surgical sterilization, has received regulatory approval in Europe. Commercialization of this highly cost effective, convenient and significantly safer approach will begin in Spain through engaged partnerships followed by select European countries. Alongside FemBloc, the FemChec® is a diagnostic product that enables an ultrasound-based test to confirm procedure success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing.

    Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

    References

    1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

    2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

    Forward-Looking Statements 

    This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "pending," "intend," "believe," "suggests," "potential," "hope," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

    Contacts: 

    Investors: 

    [email protected]

    Media Contact: 

    [email protected]



    Primary Logo

    Get the next $FEMY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Nicholas Kelley Stinson

      4 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:57:48 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • New insider Nicholas Kelley Stinson claimed ownership of 125 shares (SEC Form 3)

      3 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:54:34 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Silverman Joshua

      4 - FEMASYS INC (0001339005) (Issuer)

      6/27/25 5:25:24 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JonesTrading initiated coverage on Femasys with a new price target

      JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

      7/13/21 11:41:28 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chardan Capital initiated coverage on Femasys with a new price target

      Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

      7/13/21 8:04:59 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Financials

    Live finance-specific insights

    See more
    • Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

      -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

      5/8/25 5:01:00 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

      -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

      3/27/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

      ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

      11/12/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Femasys Inc.

      SC 13D - FEMASYS INC (0001339005) (Subject)

      11/22/23 4:00:15 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

      -- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. "Securing regulatory approvals in Australia and New Zealand mark another important step in expand

      7/1/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

      ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification. The regulatory approval for the blended

      6/25/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    SEC Filings

    See more
    • Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:22:54 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by Femasys Inc.

      S-3 - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:19:58 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/1/25 9:20:38 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

      ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

      3/21/24 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

      -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

      2/6/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care